Omaxe Limited has informed the Exchange regarding Board meeting held on August 13, 2025.
OMAXE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Omaxe Limited's board, at its August 13, 2025 meeting, approved unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, revenue from operations rose to Rs 119.46 crore from Rs 80.30 crore in Q1 FY25, but the company still posted a net loss of Rs 35.83 crore (vs Rs 64.10 crore loss YoY). On a consolidated basis, revenue declined to Rs 282.24 crore from Rs 341.61 crore, with the net loss widening sharply to Rs 185.77 crore from Rs 146.98 crore. Finance costs remained high at Rs 67.03 crore (consolidated), and other equity stayed negative at Rs (388.03) crore. The auditor (BSD & Co.) issued an unmodified review report but flagged two Emphasis of Matter items: a SEBI order from July 2024 (currently stayed by SAT, next hearing October 9, 2025) and ongoing income tax demands from assessments between AY 2014-15 and 2022-23.
Despite a slight narrowing of standalone losses, the consolidated loss widened significantly and revenue declined year-on-year, signalling continued financial stress. The pending SEBI and tax matters remain overhangs, and shareholders should watch the October 9 SAT hearing closely. Management changes (new CFO Atul Banshal) and re-appointments of key directors aim to provide stability, but negative other equity and high finance costs raise concerns about the company's financial health.